Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1

  • Oncogene. 2014 Mar 27;33(13):1690-9. doi: 10.1038/onc.2013.113.
S Shin  1 L Wolgamott  1 J Tcherkezian  2 S Vallabhapurapu  1 Y Yu  3 P P Roux  2 S-O Yoon  1
Affiliations
  • 1. Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • 2. Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada.
  • 3. Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract

Protein synthesis has a key role in the control of cell proliferation, and its deregulation is associated with pathological conditions, notably Cancer. Rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1), was known to inhibit protein synthesis. However, it does not substantially inhibit protein synthesis and cell proliferation in many Cancer types. We were interested in finding a novel target in rapamycin-resistant Cancer. The rate-limiting factor for translation is eukaryotic translation initiation factor 4E (eIF4E), which is negatively regulated by eIF4E-binding protein 1 (4E-BP1). Here, we provide evidence that glycogen synthase kinase (GSK)-3β promotes cell proliferation through positive regulation of protein synthesis. We found that GSK-3β phosphorylates and inactivates 4E-BP1, thereby increasing eIF4E-dependent protein synthesis. Considering the clinical relevance of pathways regulating protein synthesis, our study provides a promising new strategy and target for Cancer therapy.

Products